

# Liquidia Access

## LIQUIDIA ACCESS PROGRAMS CAN HELP YOUR PATIENTS START AND STAY ON YUTREPIA

Specialty pharmacy providers can offer information to help patients determine which program might be best for them

## The YUTREPIA Voucher Program



The YUTREPIA Voucher Program can provide eligible patients with a one-time, 28-day supply of YUTREPIA to help them determine if it is right for them.\*

- Eligible patients will receive support and training from a specialty pharmacy
- For eligible patients wishing to continue therapy, a separate prescription is required<sup>+</sup>

\*Only available for patients who are new to YUTREPIA. \*Continued therapy beyond the Voucher Program is dependent on the patient's insurance coverage.

## The YUTREPIA Co-Pay Program

#### The YUTREPIA Co-Pay Program can provide financial assistance to eligible patients.

- This program is not available to federally insured patients (Medicare, VA TRICARE, and other federal programs)
- For eligible commercially insured patients in need of assistance affording their out-of-pocket cost for YUTREPIA
- Eligible patients may pay as little as \$0 per prescription fill for YUTREPIA, with up to \$8500 in assistance available annually


## The YUTREPIA Bridge Program




The YUTREPIA Bridge Program can provide eligible patients who cannot immediately access their prescribed medication with a one-time, 28-day supply of YUTREPIA.

• For eligible patients who have a lapse in insurance coverage or encounter insurance authorization issues that could delay or temporarily prevent them from accessing YUTREPIA

## The YUTREPIA Patient Assistance Program



• For eligible patients with a total household adjusted gross income no greater than 500% of the federal poverty level who are unable to afford YUTREPIA due to one of the following:



• Eligible patients receive their medication for the remainder of the calendar year (subject to annual reapplication/approval)

LIQUIDIA'S PATIENT SUPPORT PROGRAMS ARE PART OF ITS CORPORATE SOCIAL RESPONSIBILITY (CSR) PROGRAM AND ARE NOT COMMERCIAL IN NATURE. PLEASE CONTACT 1-888-393-5732 FOR MORE INFORMATION.

Please see Important Safety Information on reverse and accompanying Full Prescribing Information for YUTREPIA.





## INDICATION AND IMPORTANT SAFETY INFORMATION

### INDICATION

YUTREPIA™ (treprostinil) is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.

## **IMPORTANT SAFETY INFORMATION**

#### WARNINGS AND PRECAUTIONS

- Treprostinil may cause symptomatic hypotension.
- Treprostinil inhibits platelet aggregation and increases the risk of bleeding.
- Dosage adjustments may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.
- May cause bronchospasm.
- Patients with a history of hyperreactive airway disease may be more sensitive.

#### DRUG INTERACTIONS

• Dosage adjustments may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.

#### **USE IN SPECIFIC POPULATIONS**

- Safety and effectiveness in pediatric patients have not been established.
- It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients.
- There are no adequate and well-controlled studies with YUTREPIA in pregnant women.
- There are no data on the presence of treprostinil in human milk, the effects on the breastfed infant, or the effects on milk production.
- Treprostinil has not been studied in patients with severe hepatic insufficiency.

#### **ADVERSE REACTIONS**

• Most common adverse reactions with YUTREPIA (≥10%) are cough, headache, throat irritation, and dizziness.

#### Please see accompanying Full Prescribing Information for YUTREPIA.

**LEARN HOW TO GET YOUR** PATIENTS WITH PAH AND PH-ILD **STARTED ON** YUTREPIA

Scan code



WHO = World Health Organization.

